Testing memantine for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether memantine, a drug commonly used for Alzheimer's disease, can help people with advanced prostate cancer that has stopped responding to hormone treatment. The study is especially looking for patients who also have Alzheimer's disease, but others may be able to join if they meet the main criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your prostate cancer has spread to other parts of the body and is no longer controlled by hormone therapy (this is called mCRPC).
- You have already tried one or two prior cancer treatments that did not work or stopped working.
- You can do light activities like walking or light housework (or are more active).
- You are willing to have regular check-ups and long-term follow-up visits.
- You do not have another active cancer elsewhere (except prostate cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests a cannabis-derived medicine called cannabidiol (CBD) for pain relief in men with advanced prostate cancer that has stopped responding to standard treatments. The goal is to see if CBD can help reduce pain when other options have been exhausted.
This trial tests a new treatment that targets a protein called PSMA found on prostate cancer cells. It uses a radioactive form of the treatment to try to kill cancer cells while limiting damage to healthy cells. This study is for men with advanced prostate cancer that has stopped responding to other treatments.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.